Dengue Fever Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update

Dengue is a mosquito-borne infectious disease caused by the dengue virus. Symptoms include a high fever, headaches, joint and muscle pain, vomiting, and a rash. In some cases, dengue turns into dengue hemorrhagic fever, which causes bleeding from the nose, gums, or under the skin. It can also become dengue shock syndrome, which causes massive bleeding and shock. Treatment includes the use of analgesics, fluid replacement therapy, and a healthy lifestyle.

The Dengue Fever drugs in development market research report provide comprehensive information on the therapeutics under development for Dengue Fever, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dengue Fever and features dormant and discontinued projects.

What are the key targets in the Dengue Fever pipeline products market?

The key targets in the Dengue Fever pipeline products market are Envelope Protein, Nonstructural Protein 4B, Nonstructural Protein 5, Premembrane Protein, Serine Protease NS3, Toll Like Receptor 4, Aryl Hydrocarbon Receptor, Envelope Protein M, Fibroblast Growth Factor 1, Fibroblast Growth Factor 2, and others.

Dengue Fever Pipeline Products Analysis Market by Targets

For more target insights, download a free report sample

What are the key mechanisms of action in the Dengue Fever pipeline products market?

The key mechanisms of action in the Dengue Fever pipeline products market are Nonstructural Protein 4B Inhibitor, Envelope Protein Inhibitor, Nonstructural Protein 5 Inhibitor, Serine Protease NS3 Inhibitor, Toll Like Receptor 4 Antagonist, Aryl Hydrocarbon Receptor Antagonist, Envelope Protein M Inhibitor, Fibroblast Growth Factor 1 Inhibitor, Fibroblast Growth Factor 2 Inhibitor, Flavivirin Inhibitor, and others.

Dengue Fever Pipeline Products Market Analysis by Mechanism of Actions

For more mechanism of actions insights, download a free report sample

What are the key routes of administration in the Dengue Fever pipeline products market?

The key routes of administration in the Dengue Fever pipeline products market are subcutaneous, oral, intravenous, intradermal, intramuscular, parenteral, and transdermal.

Dengue Fever Pipeline Products Market Analysis by Routes of Administration

For more routes of administration insights, download a free report sample

What are the key molecule types in the Dengue Fever pipeline products market?

The key molecule types in the Dengue Fever pipeline products market are small molecule, live attenuated vaccine, subunit vaccine, vaccine, monoclonal antibody, recombinant vector vaccine, DNA vaccine, antibody, antisense RNAi oligonucleotide, biologic, and others.

Dengue Fever Pipeline Products Market Analysis by Molecule Type

For more molecule type insights, download a free report sample

Which are the major companies in the Dengue Fever pipeline products market?

Some of the major companies in the Dengue Fever pipeline products market are BioNet-Asia Co Ltd, Emergex Vaccines Holding Ltd, Johnson & Johnson, Takeda Pharmaceutical Co Ltd, 60 Degrees Pharmaceuticals LLC, Abivax SA, Imutex Ltd, Inovio Pharmaceuticals Inc, Moleculin Biotech Inc, and Novartis AG.

Dengue Fever Pipeline Products Market Analysis by Companies

To know more about major companies, download a free report sample

Market Report Scope

Scope

• The report provides a snapshot of the global therapeutic landscape of Dengue Fever
• The report reviews pipeline therapeutics for Dengue Fever Hypogonadism by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Dengue Fever Hypogonadism therapeutics and enlists all their major and minor projects
• The report assesses Dengue Fever Hypogonadism therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA), and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews the latest news related to pipeline therapeutics for Dengue Fever

Reasons to Buy

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage
• Identify and understand important and diverse types of therapeutics under development for Dengue Fever
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and their most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Dengue Fever pipeline depth and focus on Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from the pipeline